Method of enhancing cell growth using alkyl-amine-N-oxide (AANOx)

US9464269B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9464269-B2
Application numberUS-201514717346-A
CountryUS
Kind codeB2
Filing dateMay 20, 2015
Priority dateDec 30, 2008
Publication dateOct 11, 2016
Grant dateOct 11, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to a method to enhance cell growth in culture comprising adding an alkyl-amine-n-oxide (AANOx), such as dodecyldimethylamine oxide (DDAO), into the culture medium in an amount sufficient to improve cell growth.

First claim

Opening claim text (preview).

What is claimed is: 1. A eukaryotic cell culture media comprising dodecyldimethylamine oxide (DDAO) or a related analyte in an amount sufficient to enhance cell growth when used in the culture media, wherein the analyte is selected from the group consisting of C10 dimethylamine oxide, C12 dimethyl amine oxide, C14 dimethyl amine oxide, C16 dimethylamine oxide, C18 dimethylamine oxide, dimethyl-tetradecyl-amine-oxide and dimethyl-hexadecyl-amine-oxide. 2. The media of claim 1 wherein the amount of DDAO or the related analyte is between about 4 and about 80 ppb. 3. The media of claim 1 wherein the amount of DDAO or the related analyte is between about 4 and about 50 ppb. 4. The media of claim 1 wherein the amount of DDAO or the related analyte is between about 10 ppb and about 40 ppb. 5. The media of claim 1 , wherein the culture media is animal protein-free media. 6. The media of claim 1 , wherein the culture media comprises animal protein. 7. The media of claim 1 wherein the cells are mammalian cells. 8. The media of claim 1 , wherein the cells are selected from the group consisting of BSC cells, LLC-MK cells, CV-1 cells, COS cells, VERO cells, MDBK cells, MDCK cells, CRFK cells, RAF cells, RK cells, TCMK-1 cells, LLCPK cells, PK15 cells, LLC-RK cells, MDOK cells, BHK-21 cells, CHO cells, NS-1 cells, MRC-5 cells, WI-38 cells, BHK cells, 293 cells, and RK cells.

Assignees

Inventors

Classifications

  • Amines, e.g. putrescine · CPC title

  • Serum-free medium, which may still contain naturally-sourced components · CPC title

  • C12N5/0043Primary

    Medium free of human- or animal-derived components · CPC title

  • from plants · CPC title

  • Serum-free culture media · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9464269B2 cover?
The present invention relates to a method to enhance cell growth in culture comprising adding an alkyl-amine-n-oxide (AANOx), such as dodecyldimethylamine oxide (DDAO), into the culture medium in an amount sufficient to improve cell growth.
Who is the assignee on this patent?
Baxalta Inc, Baxalta GmbH
What technology area does this patent fall under?
Primary CPC classification C12N5/0043. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Oct 11 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).